South Korea, 33% of Patients Who Took Remdesivir Showed Positive Result While 55.5% Showed No Change

Remdesivir (Develop name GS-5734), which was specially imported as a coronavirus treatment and administered to severe patients, has shown to improve conditions of one in three patients.

However, it is unclear whether the cause was an effect of medication since there have been cases where health has deteriorated while taking Remdesivir.

Kwon Joon-wook, the deputy director of the Central Disaster Control Headquatersof Suth Korea, said in a regular briefing held at the Centers for Disease Control in Osong, North Chungcheong Province, on the afternoon of the 11th,

"Remdesivir has been supplied to a total of 42 serious patients by yesterday (11th). "Remdesivir is an anti-viral drug from U.S. pharmaceutical company, Gilead Sciences.

The company is known to be effective in treating a wide range of viral diseases, including MERS and SARS. In addition, many positive research results were reported, such as speeding up the recovery time of patients with severe Coronavirus.

Hence, the government decided to import Remdesivir for special cases and was distributed to patients with severe conditions from the 1st to 10th of July, free of charge.

In principle, up to 6 bottles of Remdesivir can be taken in five days, although the period can be extended to maximum of 10 days.

Kwon announced the results of the severity change in 27 out of 42 patients who have been administered as followed.

- 15 cases in which the status has not changed

- 9 cases where the status seems to have improved

- 3 cases in which the status worsened.

Therefore, 55.6% of patients who took Remdesivir medication had no change in symptoms and 33.3% had improved symptom and 11.1 % had worsened symptoms.

However, the effect of Remdesivir cannot be measured soley on its effect on patients' symptoms. To check the effectiveness of the drug, the government should compare the conditions of patients who received Remdesivir with those who did not.

Kwon further added, in principle, we can only talk about the effectiveness of the treatment if we compare perfectly the changes in the state of the experimental group and the control group of Remdesivir.

It is also unclear whether the improvement is caused by drugs or by the patient's own immune system. It is premature to judge the effect of administering the Remdesivir treatment. We need to seek more professional judgment from the National Clinical Commission.

#Remdesivir #Gilead #Coronavirus #BTC #Blockchain #Crypto #DailyCoinNews #AML #DLT #Libra #stablecoin #Exchange #AI #Cryptocurrency #digitalCurrency #IoT #Hacker #cyberattack #SatoshiNakamoto #tradeWar #SEC #cryptowallet #FinCEN #Gemini #itBit #Kraken #Bitstamp #Liquid #OkEx #Poloniex #bitFlyer #Bitfinex #OKCoin #USDT #Hacker #Coinbase #Reddit #BitMEK #Bitfinex #forensics #Binance

 

Reporter Gina lee (news@dailycoinews.com)의 기사 더 보기

- Daily Coin News prioritizes the voice from the scene over others(news@dailycoinews.com) -

- 기사에 사용된 모든 자료에 대한 책임은 작성자 본인에게 있습니다 -

[copyrightⓒ 2018 All rights reserved by Daily Coin News]

Bitcoin price when registering article
BTC-USD : $ 9,289.91 USD (API by Bitfinex)

1 0 Write